Navigation Links
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Date:6/24/2008

y is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or condu
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
11. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Certified healthcare providers who have already immunized patients ... flu virus may now offer the vaccine to ... announced today. ,, Pennsylvania is expanding the ... million doses of vaccine have been allocated to ... the priority groups. ,, "Many certified providers have ...
(Date:12/15/2009)... Dec. 15 Reportlinker.com announces ... is available in its catalogue: ,, ... Industry in the U.S. and its ... ,, http://www.reportlinker.com/p0167745/Surgical-and-Medical-Instrument-Manufacturing-Industry-in-the-US-and-its-International-Trade-[Q4-2009-Edition].html ,, The ... and Medical Instrument Manufacturing Industry report ...
(Date:12/15/2009)... NEW YORK, Dec. 15 ... research report is available in its ... A strategic assessment of the competitive ... highest priority management responsibilities, the task ... profitability. Timely and factual competitive intelligence ...
Breaking Medicine Technology:Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients 2Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 2Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 3Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 4Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 5Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 6Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 7Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 8Reportlinker Adds Top Ten World's Leading Orthopedics Companies 2Reportlinker Adds Top Ten World's Leading Orthopedics Companies 3Blood Test May Spot Pancreatic Cancer Early 55921 1Blood Test May Spot Pancreatic Cancer Early 55921 2Inhibition of NF kappa B a key inflammatory protein reduced radiation toxicity in zebrafish 55919 1Inhibition of NF kappa B a key inflammatory protein reduced radiation toxicity in zebrafish 55919 2Promising new target emerges for autoimmune diseases 55916 1Promising new target emerges for autoimmune diseases 55916 2Promising new target emerges for autoimmune diseases 55916 3
... 11, 2007,/PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today,provided ... currently in ongoing,Phase 2 clinical trials in ... lymphoma patients. R788 is a novel,oral syk ... mast cells,macrophages and B-cells that promote swelling, ...
... WIRE)--Apr 11, 2007 - New data,supporting the clinical ... investigational oral protease inhibitors for the,treatment of hepatitis ... 42nd Annual Meeting of the European Association for ... week. In total, nine,abstracts related to telaprevir have ...
Other Medicine Technology:Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 2Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 3Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 2Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 3Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 5Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 6
(Date:12/15/2009)... strength than needed for protection, CDC says, , , TUESDAY, ... of H1N1 swine flu vaccine have been recalled by ... potency, federal health officials said Tuesday. , According to ... company,s routine testing of the vaccine for children aged ... batches had lower than required potency levels. "This means ...
(Date:12/15/2009)... will train advocates to be leaders in the ... with support from experts in online learning, the ... Dec. 15 ONE and ... applications for the first-ever "Malaria Griots" program, a ... participants to become leaders in the fight against ...
(Date:12/15/2009)... PLAINS, N.Y., Dec. 15 Team In ... groundbreaking charity sports training program, has ... to support blood cancer research and patient services. ... been the pre-eminent charity endurance sports training program, ... marathon, half marathon, triathlon, 100-mile century cycle ride ...
(Date:12/15/2009)... The new compact LifeSpan TR200 folding treadmill, made by ... was highly praised by treadmill review groups in recent ... TR200 folding treadmill received awards for Best New Treadmill, ... ,, The compact LifeSpan TR200 treadmill is designed for ... category buster is a very compact treadmill that could ...
(Date:12/15/2009)... known to reduce depression and fatigue in people struggling ... effect stems from an individual,s sense of mastery over ... achieve certain physical goals. , The study appears ... base our arguments on fatigue being a symptom of ... community health at the University of Illinois and lead ...
Breaking Medicine News(10 mins):Health News:Large Recall of Children's Swine Flu Vaccine 2Health News:ONE and Malaria No More Launch 'Malaria Griots' 2Health News:ONE and Malaria No More Launch 'Malaria Griots' 3Health News:ONE and Malaria No More Launch 'Malaria Griots' 4Health News:$1 Billion - For Charity! 2Health News:$1 Billion - For Charity! 3Health News:Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill 2Health News:Mastery of physical goals lessens disease-related depression and fatigue 2
... Are Starting to Embrace Use of Targeted Agents ... from Decision Resources WALTHAM, Mass., April 28 ... and advisory firms focusing on pharmaceutical and healthcare ... and Roche/Chugai,s Xeloda, Indian brand/generics (capecitabine) will dominate ...
... reports show Google lobbied on the electronic medical ... contradicting the Internet giant,s earlier claims that Consumer ... false."Google,s report shows a total expenditure of $880,000 ... health-related initiatives; issues relating to online personal health ...
... LANSING, Mich., April 28 Richard E. Smith, M.D., ... installed as the 144th president of the Michigan State ... annual MSMS House of Delegates meeting in Grand Rapids. ... the first African American to serve as MSMS president, ...
... at the Swedish medical university Karolinska Institutet have shown ... provide valuable support for healthcare in low and mid-income ... procedure is based on a simple blood test and, ... greater number of patients receive the right treatment at ...
... 28 /PRNewswire-FirstCall/ - Medical International Technology Inc. (MDLH. PK) ... is pleased to announce that it has received a ... This private investment from our partners is an important ... a commitment towards MIT,s technology and products. ...
... HOUSTON, April 28 Research promoting ... saliva, will be revealed Friday, May 15, at ... Annual Meeting & Clinical Congress in Houston, Texas.(Logo: ... )While searching for biomarkers that may indicate diabetes, ...
Other Medicine News:Health News:Sanofi-Aventis' and Roche/Chugai's Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013 2Health News:Consumer Watchdog: U.S. Senate Records Reveal Google Inc. Lobbying Campaign on Personal Medical Records Law Despite Internet Giant's Denials 2Health News:Consumer Watchdog: U.S. Senate Records Reveal Google Inc. Lobbying Campaign on Personal Medical Records Law Despite Internet Giant's Denials 3Health News:Richard E. Smith, M.D., Installed as President of Michigan State Medical Society 2Health News:Richard E. Smith, M.D., Installed as President of Michigan State Medical Society 3Health News:Simple blood test proves powerful ally in the fight against malaria 2Health News:MIT is pleased to announce that it has received a US$ 200,000 private placement from its future Chinese partners 2Health News:Detecting Diabetes Without a Needle: The Spit Factor 2
... of Protein C Activity by ... free of Protein C; highly ... contortrix venom for specific activation ... an activator selected specially for ...
Immuno-turbidimetric Assay for Antithrombin III Antigen. Suspension of microlatex particles coated with specific antibodies....
Immuno-turbidimetric Assay for Protein S Antigen. Suspension of microlatex particles coated with specific antibodies....
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Medicine Products: